Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): An open-label prospective study of time in treatment, dose, side-effects and comorbidity

European Neuropsychopharmacology

Volumn 24, Issue 12, 2014, Pages 1873-1884

  Fredriksen, Mats ^a,b   Dahl, Alv A ^b,c   Martinsen, Egil W ^b,d   Klungsøyr, Ole ^b,d   Haavik, Jan ^e,f   Peleikis, Dawn E ^g  

^a VESTFOLD HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

ADHD; ADHD medications; Comorbidity; Psychopharmacology; Psychostimulants; Side effects

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; SEDATIVE AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADULT; ADULT DISEASE; AGITATION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HEART PALPITATION; HEART RATE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL INSTABILITY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; PSYCHOPHARMACOLOGY; STOMACH PAIN; SUBSTANCE ABUSE; TIC; TIME; TREATMENT DURATION; XEROSTOMIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; DOSE RESPONSE; LONGITUDINAL STUDY; MEDICATION COMPLIANCE; MENTAL STRESS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; YOUNG ADULT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; METHYLPHENIDATE; PROPYLAMINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; STRESS, PSYCHOLOGICAL; TIME FACTORS; YOUNG ADULT;

EID: 84919334964     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.09.013     Document Type: Article

References (53)

1. Aas I.H. Guidelines for rating global assessment of functioning (GAF). Ann. Gen. Psychiatry 2011, 10(Epub, Jan 20). 10.1186/1744-859X-10-2.
2. Adler L.A., Orman C., Starr H.L., Silber S., Palumbo J., Cooper K., et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J. Clin. Psychopharmacol. 2011, 31:108-114.
3. Adler L.A., Spencer T., Brown T.E., Holdnack J., Saylor K., Schuh K., et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J. Clin. Psychopharmacol. 2009, 29:44-50.
4. Adler L.A., Spencer T., McGough J.J., Jiang H., Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J. Atten. Disord. 2009, 12:449-459.
5. Adler L.A., Spencer T.J., Williams D.W., Moore R.J., Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J. Atten. Disord. 2008, 12:248-253.
6. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, (text revision), American Psychiatric Association, Washington, DC. 4th ed.
7. Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Association, American Psychiatric Association, Arlington. 5th ed.
8. Atkinson M., Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch. Dis. Child. Educ. Pract. Ed. 2010, 95:24-27.
9. Bejerot S., Ryden E.M., Arlinde C.M. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J. Clin. Psychiatry 2010, 71:1590-1597.
10. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Kotarski M., et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. 2010, 30:549-553.
11. Buitelaar J.K., Trott G.E., Hofecker M., Waechter S., Berwaerts J., Dejonkheere J., et al. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int. J. Neuropsychopharmacol 2011, 15:1-13.
12. CADDRA Canadian ADHD Practice Guidelines 2008, Canadian Attention Deficit Hyperactivity Disorder Resource Alliance, Toronto.
13. Caisley H., Müller U. Adherence to medication in adults with attention deficit hyperactivity disorder and and pro re nata dosing of psychostimulants: a systematic review. Eur. Psychiatry 2012, 27:343-349.
14. Derogatis, L. R. & Savitz, K. L., 1999. The SCL-90-R, Brief Symptom Inventory, and Matching Clinical Rating Scales.
15. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33:766-771.
16. Faraone S.V., Glatt S.J. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry 2010, 71:754-763.
17. Fredriksen M., Dahl A.A., Martinsen E.W., Klungsoyr O., Faraone S.V., Peleikis D.E. Childhood and persistent ADHD symptoms associated with educational failure and long-term occupational disability in adult ADHD. Atten. Deficit Hyperact. Disord. 2014, 6:87-99.
18. Fredriksen M., Halmoy A., Faraone S.V., Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur. Neuropsychopharmacol. 2013, 23:508-527.
19. Gibbins C., Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr. Psychiatry Rep. 2007, 9:420-426.
20. Ginsberg Y., Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br. J. Psychiatry 2012, 200:68-73.
21. Gueorguieva R., Krystal J.H. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch. Gen. Psychiatry 2004, 61:310-317.
22. Guy, W. & National Institute of Mental Health, 1976. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
23. Haavik J., Halmoy A., Lundervold A.J., Fasmer O.B. Clinical assessment and diagnosis of adults with attention-deficit/hyperactivity disorder. Expert. Rev. Neurother. 2010, 10:1569-1580.
24. Hinshaw S.P., Scheffler R.M., Fulton B.D., Aase H., Banaschewski T., Cheng W., et al. International variation in treatment procedures for ADHD: social context and recent trends. Psychiatr. Serv. 2011, 62:459-464.
25. Kessler R.C., Adler L., Ames M., Demler O., Faraone S., Hiripi E., et al. The World Health Organization Adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol. Med. 2005, 35:245-256.
26. Kooij J.J.S. Diagnostic Assessment and Treatment, Pearson 2010, Amsterdam.
27. Langbehn D.R., Pfohl B.M., Reynolds S., Clark L.A., Battaglia M., Bellodi L., et al. The Iowa personality disorder screen: development and preliminary validation of a brief screening interview. J. Pers. Disord. 1999, 13:75-89.
28. Leiknes K.A., Leganger S., Malt E.A. MINI International Neuropsychiatric Interview (1992-2009). [MINI Internasjonalt neuropsykiatrisk intervju, Norwegian Translation Version 6.0.0]. Norway 2009, Mapi Research Institute, Lexington.
29. Lensing M.B., Zeiner P., Sandvik L., Opjordsmoen S. Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey. J. Clin. Psychiatry 2013, 74:e87-e93.
30. Marchant B.K., Reimherr F.W., Halls C., Williams E.D., Strong R.E. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann. Clin. Psychiatry 2010, 22:196-204.
31. Michelson D., Adler L., Spencer T., Reimherr F.W., West S.A., Allen A.J., et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry 2003, 53:112-120.
32. Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults 2009, National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence, London.
33. Diagnosis and Treatment of Hyperkinetic Disorder/Attention Deficit Hyperactivity Disorder (ADHD) in Children, Adolescents and Adults [in Norwegian] 2005, Norwegian Directorate of Health, ([IS-1244]), Sosial- og helsedirektoratet, Oslo.
34. Olsson I., Sorebo O., Dahl A.A. A cross-sectional testing of the Iowa personality disorder screen in a psychiatric outpatient setting. BMC Psychiatry 2011, 11:105.
35. Pedersen G., Hagtvet K.A., Karterud S. Generalizability studies of the global assessment of functioning-split version. Compr. Psychiatry 2007, 48:88-94.
36. Powell S.G., Thomsen P.H., Frydenberg M., Rasmussen H. Long-term treatment of ADHD with stimulants: a large observational study of real-life patients. J. Atten. Disord. 2011, 15:439-451.
37. Robison R.J., Reimherr F.W., Gale P.D., Marchant B.K., Williams E.D., Soni P., et al. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD. Ann. Clin. Psychiatry 2010, 22:94-102.
38. Rosler M., Fischer R., Ammer R., Ose C., Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:120-129.
39. Rosler M., Retz W., Fischer R., Ose C., Alm B., Deckert J., et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J. Biol. Psychiatry 2010, 11:709-718.
40. Seixas M., Weiss M., Müller U. Systematic review of national and international guidelines on attention deficit hyperactivity disorder (ADHD). J. Psychopharmacol. 2012, 26:753-765.
41. Sheehan D., Janavs J., Baker R., Harnett-Sheehan K., Knapp E., Sheehan N. Mini international neuropsychiatric interview 2002, [Norwegian Translation Version 5.0.0], University of South Florida, Tampa.
42. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
43. Stiefel G., Besag F.M. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010, 33:821-842.
44. Torgersen T., Gjervan B., Nordahl H.M., Rasmussen K. Predictive factors for more than 3 years[U+05F3] duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study. J. Clin. Psychopharmacol. 2012, 32:645-652.
45. Vitiello B., Elliott G.R., Swanson J.M., Arnold L.E., Hechtman L., Abikoff H., et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am. J. Psychiatry 2012, 169:167-177.
46. Wechsler D. WAIS-IV Manual 2008, The Psychological Corporation, New York: NY.
47. Weisler R., Young J., Mattingly G., Gao J., Squires L., Adler L. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr. 2009, 14:573-585.
48. Weiss M.D., Gadow K., Wasdell M.B. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2006, 67(Suppl 8):S38-S45.
49. Weiss M.D., Gibbins C., Goodman D.W., Hodgkins P.S., Landgraf J.M., Faraone S.V. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2010, 71:381-390.
50. Wender P.H., Reimherr F.W., Marchant B.K., Sanford M.E., Czajkowski L.A., Tomb D.A. A one year trial of methylphenidate in the treatment of ADHD. J. Atten. Disord. 2011, 15:36-45.
51. Young J.L., Sarkis E., Qiao M., Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin. Neuropharmacol. 2011, 34:51-60.
52. Zetterqvist J., Asherson P., Halldner L., Langstrom N., Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr. Scand. 2013, 128:70-77.
53. Zoega H., Furu K., Halldorsson M., Thomsen P.H., Sourander A., Martikainen J.E. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr. Scand. 2011, 123:360-367.